Hester Biosciences Ltd · HESTERBIO⚠ unverified
—
—
—
—
—
₹75 Cr
₹67 Cr
₹88 Cr
₹70 Cr
₹67 Cr
₹79 Cr
₹82 Cr
₹84 Cr
₹63 Cr
₹82 Cr
₹84 Cr
₹71 Cr
₹77 Cr
₹100 Cr
₹77 Cr
20-quarter listed-company comparison
Pharma - Animal Stocks in India
Pharma - Animal: Viyash Scientific Ltd owns the largest revenue base AND the fastest current growth.
01 · the index people search for
Nifty Pharma - Animal Index — Constituents & Performance
The Pharma - Animal companies below are the listed Indian Pharma - Animal universe this page tracks — the same constituent set people search for as the Nifty Pharma - Animal index. Every figure is equal-weighted across those companies, so one large constituent cannot set the reading. Each number carries its own as-of date.
02 · the sector itself · before any single company
How has Pharma - Animal moved against NIFTY 500?
The line below covers up to 5.2 years and opens on the 5Y view; the buttons cut it shorter. Over the most recent two of them this sector is 50% ahead of NIFTY 500. Earnings across its companies grew 79% on average over the last four reported quarters. It has been ahead of NIFTY 500 on a rolling three-month view for 28 weeks running.
LEADER · ahead 28w✓Price and the fundamentals both up3 of 3 companies ahead of NIFTY 500 by 5% or more over three months
RS ↑28w · 3/3 >200d (+0) · 3/3 lead (+0) · EPS 3/3↑
Pharma - Animal, equal-weighted, based at 200
NIFTY 500, same base, same start
trailing 12-month earnings per share rising
falling
Pharma - Animal, equal-weighted, based at 200
NIFTY 500, same base, same start
trailing 12-month earnings per share rising
falling
Pharma - Animal, equal-weighted, based at 200
NIFTY 500, same base, same start
trailing 12-month earnings per share rising
falling
Both lines start at 200 in the same week, so the distance between them is the whole story: the sector line is an equal-weighted index of its 3 companies. The bars underneath are trailing 12-month earnings per share, one bar per reported quarter, each member rebased to 100 at the start and the sector taking the median — so a price line pulling away from flat bars is a re-rating, not earnings. A bar turns red when that figure is lower than the quarter before. Rules are fixed and applied identically everywhere on this site: ahead by 5% or more over three months, or behind by 20% or more over a year while earnings grew 20% or more. Hover any point to read both values and the gap. This is a description of what the numbers did, not advice.
03 · sector relative strength, before individual stocks
Is Pharma - Animal outperforming NIFTY 500?
Pharma - Animal has outperformed NIFTY 500 by 80.1% over the last 52 weeks. Over 13 weeks the gap is a lead of 34.1%. 3 of 3 covered companies currently beat NIFTY on Mansfield relative strength, so leadership inside the sector is selective. NGL Fine Chem Ltd is the strongest against the sector itself at +16.5%.
+34.1%Sector vs NIFTY 500 · 13 weeks
+80.1%Sector vs NIFTY 500 · 52 weeks
3/3Stocks leading NIFTY 500
1/3Stocks leading sector
Sector metric: 31.4 as of 2026-08-09 · CONSOLIDATION · falling.
The central tension: current leadership is concentrated, so durability matters more than rank.
Start with scale. Then earnings trajectory. Then business quality. Only after those three agree should price leadership carry much weight.
Bottom line
Pharma - Animal has outperformed NIFTY 500 by 80.1% over 52 weeks and 34.1% over 13 weeks. 3 of 3 covered companies beat NIFTY on Mansfield relative strength, while 1 of 3 beat the sector itself. Viyash Scientific Ltd leads with revenue of ₹3,069 crore, based on 3 of 3 comparable companies through Mar 2026.
Companies
3
complete canonical membership
Combined market value
₹16.3K Cr
Viyash Scientific Ltd
Revenue growing
3/3
positive TTM year-on-year growth
Beating NIFTY 500
3/3
positive Mansfield relative strength
Comparing 3 of 3
04 · research priority, made explicit
Best Pharma - Animal Stocks in India (Aug 2026), Ranked by Data
4-Factor Sector Score
An additive sector-relative research score. The four displayed point contributions always equal the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or stale evidence is absorbed inside the affected factor, never applied as a hidden adjustment.
Growth & earnings · 35%Capital efficiency · 25%Valuation · 20%Relative strength · 20%
NGL Fine Chem Ltd has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 79.8% evidence confidence.
How this score is built, and what the marks mean
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Top 10 Pharma - Animal Stocks in India
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1NGL Fine Chem LtdNGLFINE | 71.6/100Favorable setup80% evidence | LEADER | 32.1/35 Revenue 36.1% · PAT 100% · OPM change 7 pp 83% evidence | 17.2/25 ROCE 18.6% · OPM 14% 95% evidence | 8.3/20 P/E 39.5× · PEG — 35% evidence | 14.0/20 RS sector 16.5% · RS bench 63% · 1Y 160.2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 32.1 + 17.2 + 8.3 + 14 = 71.6 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Hester Biosciences LtdHESTERBIO | 61.0/100Mixed-positive evidence78% evidence | BREAKING OUT | 27.4/35 Revenue 3.8% · PAT 100% · OPM change 2 pp 95% evidence | 14.1/25 ROCE 15.2% · OPM 29% 95% evidence | 11.5/20 P/E 38.7× · PEG — 35% evidence | 8.0/20 RS sector -29.2% · RS bench 33% · 1Y 10.2%11 of 11 weeks ahead 70% evidence |
| Exact sum: 27.4 + 14.1 + 11.5 + 8 = 61 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Viyash Scientific LtdVIYASH | 47.2/100Mixed-negative evidence86% evidence | LEADER | 26.1/35 Revenue 58.6% · PAT 100% · OPM change 8 pp 88% evidence | 11.1/25 ROCE 13.4% · OPM 20% 100% evidence | 5.0/20 P/E 61.3× · PEG 3.8 50% evidence | 5.0/20 RS sector -14.7% · RS bench 24.1% · 1Y 64.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 26.1 + 11.1 + 5 + 5 = 47.2 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -14.7% and the one-year return is 64.3%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
05 · what price has already done
Market action
NGL Fine Chem Ltd has the strongest one-year price move in Pharma - Animal at +160.2%. It also leads on Mansfield relative strength against NIFTY at +63%. 3 of 3 covered companies are above zero on that measure. Every line covers 313 weekly closes through 2026-08-07.
Price and relative strength
Every company, the sector's own index and NIFTY 500 all start level on the left edge of the window, so only the distance between the lines counts — the highest line has risen the most since then, and the chart at the top of this page is drawn the same way. It opens on one year; the buttons beside it stretch that to three or five.
How far ahead of or behind NIFTY 500 each company has been running, measured against its own recent average of that comparison, so the flat line at zero IS NIFTY 500: above it the company is beating the market, below it the market is beating the company. It opens on one year.
The same measure taken against Pharma - Animal itself instead of the whole market, so the flat line at zero is the sector: above it the company is beating its own peers, which is the sharper test of the two. It opens on one year.
06 · compare level, then change
Revenue Scale & Growth Durability
Viyash Scientific Ltd has the highest Revenue among the 3 Pharma - Animal companies compared here, at ₹3,069 crore. NGL Fine Chem Ltd is next at ₹501 crore. The same company also holds the highest Revenue growth, at 58.6%. 3 of 3 companies report a comparable reading, the latest through Mar 2026.
What the numbers say: Viyash Scientific Ltd is the scale leader at ₹3,069 crore, 512.6% ahead of NGL Fine Chem Ltd. Viyash Scientific Ltd's growth is 58.6% from a ₹3,069 crore base, with 19 reported observations in the 20-quarter window. Treat the growth leader as an acceleration candidate, not as equally proven scale.
LeaderViyash Scientific Ltd · ₹3,069 crore
Gap512.6% versus #2 · NGL Fine Chem Ltd
Persistence8/8 recent comparable periods
Coverage3/3 companies · 48 observations
Investor read: Viyash Scientific Ltd is the scale benchmark; Viyash Scientific Ltd is the acceleration watch. Promote the challenger only if growth persists and converts into margin and returns.
This conclusion weakens if: Viyash Scientific Ltd's growth falls below Viyash Scientific Ltd's for two consecutive comparable reports while operating margin also compresses.
Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.
Revenuelargest
Revenue growthfastest growers
Revenue · company comparison
3/3 level · 3/3 change
On every company-comparison chart on this page: solid lines show level, dotted lines show change when “Both” is selected, and a missing report breaks the line rather than being invented.
All-company data · latest reported quarter
In every all-company table on this page, each figure is the company’s latest single reported quarter. The rankings above them use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | Revenue | Revenue growth | Reported |
|---|---|---|---|
| Viyash Scientific Ltd VIYASH | ₹920 Cr | 129% | Mar 2026 |
| NGL Fine Chem Ltd NGLFINE⚠ unverified | ₹149 Cr | 57% | Mar 2026 |
| Hester Biosciences Ltd HESTERBIO⚠ unverified | ₹77 Cr | -8.3% | Jun 2026 |
Full 20-quarter history · every available company
Revenue · reported quarter history
NGL Fine Chem Ltd · NGLFINE⚠ unverified
—
—
—
—
—
₹72 Cr
₹75 Cr
₹71 Cr
₹80 Cr
₹88 Cr
₹100 Cr
₹91 Cr
₹93 Cr
₹89 Cr
₹95 Cr
₹104 Cr
₹120 Cr
₹128 Cr
₹149 Cr
—
Viyash Scientific Ltd · VIYASH
₹351 Cr
₹358 Cr
₹384 Cr
₹341 Cr
₹338 Cr
₹375 Cr
₹367 Cr
₹333 Cr
₹346 Cr
₹329 Cr
₹361 Cr
₹390 Cr
₹369 Cr
₹774 Cr
₹402 Cr
₹441 Cr
₹850 Cr
₹858 Cr
₹920 Cr
—
Revenue growth · reported quarter history
Hester Biosciences Ltd · HESTERBIO⚠ unverified
—
—
—
—
—
—
—
—
—
-11%
18%
-6.8%
20%
-6.0%
3.8%
2.4%
-15%
22%
22%
-8.3%
NGL Fine Chem Ltd · NGLFINE⚠ unverified
—
—
—
—
—
—
—
—
—
22%
33%
28%
16%
1.1%
-5.0%
14%
29%
44%
57%
—
Viyash Scientific Ltd · VIYASH
—
—
—
6.2%
-3.7%
4.8%
-4.4%
-2.4%
2.4%
-12%
-1.6%
17%
6.7%
135%
11%
13%
130%
11%
129%
—
07 · compare level, then change
Operating Economics & Margin Trend
Hester Biosciences Ltd has the highest OPM among the 3 Pharma - Animal companies compared here, at 29%. Viyash Scientific Ltd is next at 20%. Viyash Scientific Ltd has the highest Margin change at +8 percentage points, so level and change sit with different companies. 3 of 3 companies report a comparable reading, the latest through Jun 2026.
What the numbers say: Hester Biosciences Ltd leads opm at 29%; Viyash Scientific Ltd leads margin change at +8 percentage points.
LeaderHester Biosciences Ltd · 29%
Gap45% versus #2 · Viyash Scientific Ltd
Persistence6/8 recent comparable periods
Coverage3/3 companies · 58 observations
Investor read: Hester Biosciences Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current margin change signal.
Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.
OPMhighest
Margin changefastest expanders
Operating margin · company comparison
3/3 level · 3/3 change
All-company data · latest reported quarter
| Company | OPM | Margin change | Reported |
|---|---|---|---|
| Hester Biosciences Ltd HESTERBIO⚠ unverified | 29% | +2.0 pp | Jun 2026 |
| Viyash Scientific Ltd VIYASH | 20% | +8.0 pp | Mar 2026 |
| NGL Fine Chem Ltd NGLFINE⚠ unverified | 14% | +7.0 pp | Mar 2026 |
Full 20-quarter history · every available company
OPM · reported quarter history
Hester Biosciences Ltd · HESTERBIO⚠ unverified
28%
27%
18%
15%
17%
25%
17%
16%
19%
15%
20%
21%
23%
8.0%
23%
27%
17%
23%
34%
29%
NGL Fine Chem Ltd · NGLFINE⚠ unverified
22%
15%
13%
3.3%
14%
14%
19%
14%
17%
16%
16%
10%
12%
6.0%
7.0%
11%
14%
18%
14%
—
Viyash Scientific Ltd · VIYASH
5.6%
10%
8.7%
0.6%
0.9%
3.0%
-0.9%
-2.5%
4.4%
7.0%
9.0%
11%
11%
13%
12%
12%
20%
20%
20%
—
Margin change · reported quarter history
Hester Biosciences Ltd · HESTERBIO⚠ unverified
−1.6 pp
−10.2 pp
−12.5 pp
−13.7 pp
−10.6 pp
−2.0 pp
−1.3 pp
+1.4 pp
+1.6 pp
−10.0 pp
+3.0 pp
+5.0 pp
+4.0 pp
−7.0 pp
+3.0 pp
+6.0 pp
−6.0 pp
+15.0 pp
+11.0 pp
+2.0 pp
NGL Fine Chem Ltd · NGLFINE⚠ unverified
−8.0 pp
−15.4 pp
−16.4 pp
−27.8 pp
−8.4 pp
−1.4 pp
+6.4 pp
+10.7 pp
+3.5 pp
+2.0 pp
−3.0 pp
−4.0 pp
−5.0 pp
−10.0 pp
−9.0 pp
+1.0 pp
+2.0 pp
+12.0 pp
+7.0 pp
—
Viyash Scientific Ltd · VIYASH
−11.2 pp
−8.1 pp
−3.3 pp
−5.7 pp
−4.8 pp
−7.1 pp
−9.6 pp
−3.1 pp
+3.6 pp
+4.0 pp
+9.9 pp
+13.5 pp
+6.6 pp
+6.0 pp
+3.0 pp
+1.0 pp
+9.0 pp
+7.0 pp
+8.0 pp
—
08 · compare level, then change
Profit Scale & Acceleration
Viyash Scientific Ltd has the highest Net profit among the 3 Pharma - Animal companies compared here, at ₹206 crore. Hester Biosciences Ltd is next at ₹137 crore. Hester Biosciences Ltd has the highest Profit growth at the 100% top of the scoring scale, so level and change sit with different companies.
What the numbers say: Viyash Scientific Ltd leads with ₹206 crore of TTM profit, 50.4% above Hester Biosciences Ltd. Hester Biosciences Ltd shows ≥100% on the scoring scale (260.5% uncapped) growth from a ₹137 crore profit base. Compare the size of the base and persistence before ranking acceleration above profit scale.
LeaderViyash Scientific Ltd · ₹206 crore
Gap50.4% versus #2 · Hester Biosciences Ltd
Persistence6/8 recent comparable periods
Coverage3/3 companies · 48 observations
Investor read: Viyash Scientific Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.
Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.
Net profitlargest
Profit growthfastest growers
Net profit · company comparison
3/3 level · 3/3 change
All-company data · latest reported quarter
| Company | Net profit | Profit growth | Reported |
|---|---|---|---|
| Hester Biosciences Ltd HESTERBIO⚠ unverified | ₹97 Cr | 471% | Jun 2026 |
| Viyash Scientific Ltd VIYASH | ₹66 Cr | 560% | Mar 2026 |
| NGL Fine Chem Ltd NGLFINE⚠ unverified | ₹13 Cr | 1,200% | Mar 2026 |
Full 20-quarter history · every available company
Net profit · reported quarter history
Hester Biosciences Ltd · HESTERBIO⚠ unverified
—
—
—
—
—
₹12 Cr
₹6 Cr
₹7 Cr
₹4 Cr
₹4 Cr
₹6 Cr
₹7 Cr
₹8 Cr
₹11 Cr
₹2 Cr
₹17 Cr
₹14 Cr
₹9 Cr
₹17 Cr
₹97 Cr
NGL Fine Chem Ltd · NGLFINE⚠ unverified
—
—
—
—
—
₹6 Cr
₹9 Cr
₹9 Cr
₹10 Cr
₹10 Cr
₹12 Cr
₹9 Cr
₹10 Cr
₹1 Cr
₹1 Cr
₹9 Cr
₹10 Cr
₹16 Cr
₹13 Cr
—
Viyash Scientific Ltd · VIYASH
₹14 Cr
₹19 Cr
₹10 Cr
₹-14 Cr
₹-4 Cr
₹-10 Cr
₹-92 Cr
₹-35 Cr
₹-7 Cr
₹11 Cr
₹1 Cr
₹9 Cr
₹6 Cr
₹42 Cr
₹10 Cr
₹18 Cr
₹73 Cr
₹49 Cr
₹66 Cr
—
Profit growth · reported quarter history
Hester Biosciences Ltd · HESTERBIO⚠ unverified
—
—
—
—
—
—
—
—
—
-67%
0.0%
0.0%
100%
175%
-67%
143%
75%
-18%
750%
471%
NGL Fine Chem Ltd · NGLFINE⚠ unverified
—
—
—
—
—
—
—
—
—
67%
33%
0.0%
0.0%
-90%
-92%
0.0%
0.0%
1,500%
1,200%
—
Viyash Scientific Ltd · VIYASH
—
—
—
-567%
-129%
-153%
-1,020%
—
—
—
—
—
—
282%
900%
100%
1,117%
17%
560%
—
09 · compare level, then change
Return On Capital Employed
NGL Fine Chem Ltd has the highest ROCE among the 3 Pharma - Animal companies compared here, at 18.6%. Hester Biosciences Ltd is next at 15.2%. The same company also holds the highest ROCE change, at +6.5 percentage points. 3 of 3 companies report a comparable reading, the latest through Mar 2026.
What the numbers say: NGL Fine Chem Ltd leads ROCE at 18.6%, 3.4 percentage points above Hester Biosciences Ltd. NGL Fine Chem Ltd has the strongest latest improvement at +6.5 percentage points. Read the leader beside the density of its reported history: a sparse high return is a candidate; a repeated high return is evidence of durability.
LeaderNGL Fine Chem Ltd · 18.6%
Gap22.4% versus #2 · Hester Biosciences Ltd
Persistence3/8 recent comparable periods
Coverage3/3 companies · 45 observations
Investor read: NGL Fine Chem Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current roce change signal.
ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.
ROCEhighest
ROCE changefastest improvers
Return on capital · company comparison
3/3 level · 3/3 change
All-company data · latest reported quarter
| Company | ROCE | ROCE change | Reported |
|---|---|---|---|
| NGL Fine Chem Ltd NGLFINE⚠ unverified | 13% | +6.5 pp | Mar 2026 |
| Hester Biosciences Ltd HESTERBIO⚠ unverified | 13% | +4.6 pp | Jun 2026 |
| Viyash Scientific Ltd VIYASH | 8.7% | −0.5 pp | Mar 2026 |
Full 20-quarter history · every available company
ROCE · reported quarter history
Hester Biosciences Ltd · HESTERBIO⚠ unverified
19%
—
12%
—
7.9%
—
8.1%
—
8.7%
8.3%
7.7%
10%
9.5%
11%
8.6%
11%
7.5%
13%
13%
—
NGL Fine Chem Ltd · NGLFINE⚠ unverified
42%
—
27%
—
12%
—
11%
—
16%
22%
16%
23%
13%
16%
6.7%
10%
7.3%
16%
13%
—
Viyash Scientific Ltd · VIYASH
11%
—
6.2%
—
3.0%
—
-1.4%
—
-2.0%
-11%
2.5%
7.1%
8.1%
11%
9.2%
14%
11%
25%
8.7%
—
ROCE change · reported quarter history
Hester Biosciences Ltd · HESTERBIO⚠ unverified
—
—
—
—
−11.0 pp
—
−3.7 pp
—
+0.8 pp
—
−0.4 pp
—
+0.8 pp
+2.7 pp
+0.9 pp
+0.5 pp
−2.0 pp
+1.5 pp
+4.6 pp
—
NGL Fine Chem Ltd · NGLFINE⚠ unverified
—
—
—
—
−30.5 pp
—
−15.9 pp
—
+4.5 pp
—
+4.4 pp
—
−3.5 pp
−6.2 pp
−8.8 pp
−12.2 pp
−5.2 pp
+0.2 pp
+6.5 pp
—
Viyash Scientific Ltd · VIYASH
—
—
—
—
−7.7 pp
—
−7.6 pp
—
−5.0 pp
—
+3.9 pp
—
+10.1 pp
+21.8 pp
+6.7 pp
+6.6 pp
+2.5 pp
+13.3 pp
−0.5 pp
—
10 · compare level, then change
Valuation Against Growth & Quality
Viyash Scientific Ltd has the lowest PEG among the 3 Pharma - Animal companies compared here, at 3.8×. Hester Biosciences Ltd has the lowest P/E at 38.7×, so level and change sit with different companies. 1 of 3 companies report a comparable reading, the latest through Mar 2026.
What the numbers say: Viyash Scientific Ltd has the lowest comparable PEG at 3.8×. Only 1 of 3 companies have earnings and growth steady enough for the ratio to mean anything, so no broad “cheapest stock” conclusion is defensible unless the current multiple, own-history position and growth durability agree.
LeaderViyash Scientific Ltd · 3.8×
GapNot enough peers
Persistence0/8 recent comparable periods
Coverage1/3 companies · 1 observations
Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.
This conclusion weakens if: The next two comparable reports reverse the current p/e signal.
PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is recomputed consistently as the trailing P/E divided by that growth rate — reported earnings, never an expected-earnings multiple. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing.
PEGlowest PEG
P/Elowest P/E
Valuation · company comparison
1/3 level · 3/3 change
All-company data · latest reported quarter
| Company | PEG | P/E | Reported |
|---|---|---|---|
| Viyash Scientific Ltd VIYASH | 3.8 | 43.8 | Mar 2026 |
| NGL Fine Chem Ltd NGLFINE⚠ unverified | — | 37.4 | Mar 2026 |
| Hester Biosciences Ltd HESTERBIO⚠ unverified | — | 35.4 | Jun 2026 |
Full 20-quarter history · every available company
PEG · reported quarter history
Viyash Scientific Ltd · VIYASH
3.8
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
P/E · reported quarter history
Hester Biosciences Ltd · HESTERBIO⚠ unverified
49.2
45.7
49.2
43.7
55.6
56.2
43.5
54.7
49.6
48.3
64.2
108.1
109.2
86.9
34.3
57.1
43.5
30.8
27.4
35.4
NGL Fine Chem Ltd · NGLFINE⚠ unverified
26.6
25.9
20.6
20.3
29.3
43.4
39.9
55.2
41.8
39.6
33.7
35.1
30.3
27.1
21.1
30.9
41.2
38.6
37.4
—
Viyash Scientific Ltd · VIYASH
62.1
56.1
63.7
57.7
90.0
208.6
180.1
—
—
-22.0
—
529.7
244.3
227.0
60.0
74.8
66.0
42.9
43.8
—
11 · before the conclusion, check the blind spots
What can make this comparison misleading?
This Pharma - Animal comparison names 6 specific ways its own evidence can mislead, all listed below. All 3 companies here report on comparable dates, so no rank carries a stale marker. 2 draw at least one figure from a second feed with too little overlap to cross-check. A high growth rate can still be a low-base artefact.
Keep these limits visible
- A high growth rate can be a low-base artefact. The page keeps level and change separate for that reason.
- A high ROCE can be temporary or flattered by a small capital base. Read it beside margin, cash conversion and reinvestment.
- The 4-Factor Sector Score ranks research priority, not portfolio action. Management quality, catalysts and risks need equally fresh evidence before capital is deployed.
- An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
- 2 companies draw at least one figure from a second data feed with too little overlapping history to cross-check against the primary source; they are marked unverified wherever those figures appear.
- Thin comparisons: Valuation have fewer than three usable current readings.
12 · evidence and freshness
How was this comparison built?
This comparison is built from the reported filings of 3 Pharma - Animal companies, normalized to a common ₹ scale and a shared quarter axis of up to 20 quarters each. Fundamentals run through Jun 2026 and market data through 2026-08-07. A second data feed fills gaps only after identity and scale reconciliation, and missing observations are never interpolated.
FundamentalsThrough Jun 2026 · up to 20 quarters per company
Market dataThrough 2026-08-07 · weekly price and relative-strength history
Derived metricsGrowth, changes and PEG are calculated only when their inputs are comparable.
Score confidenceMissing and stale evidence reduces confidence and pulls the 0–100 research-priority score toward neutral.
Source standing1 cross-checked · 2 unverified · 0 withheld, of 3 graded companies.
How a second data feed is admitted, and what happens when it disagrees
A second feed is read only after its reported income is matched against the primary source on at least three overlapping periods. Where the two agree the figures fill silently. Where there is too little shared history to compare, the figures are still drawn — they are the only evidence there is — and marked ⚠ unverified everywhere they appear. Where the two are known to disagree, nothing from the second feed is drawn and the affected company is named under the chart it is missing from.
13 · questions investors ask, short speakable answers
Pharma - Animal company comparison FAQs
These 23 answers restate the Pharma - Animal comparison above in question form. Every one is computed from the same 3 companies and the same reported filings as the rankings and charts, current through Jun 2026. Price and relative-strength answers run through 2026-08-07. Nothing here is estimated, and none of it is a recommendation.
Is the Pharma - Animal sector outperforming NIFTY 500?
Pharma - Animal has outperformed NIFTY 500 by 80.1% over 52 weeks and 34.1% over 13 weeks. 3 of 3 covered companies beat NIFTY on Mansfield relative strength, while 1 of 3 beat the sector itself.
Which Pharma - Animal company is largest by revenue?
Viyash Scientific Ltd leads with revenue of ₹3,069 crore, based on 3 of 3 comparable companies through Mar 2026.
Which Pharma - Animal company is growing fastest?
Viyash Scientific Ltd has the fastest current revenue growth at 58.6%, across 3 of 3 comparable companies.
Which Pharma - Animal company has the strongest 4-Factor Sector Score?
NGL Fine Chem Ltd ranks first at 71.6/100 with 79.8% evidence confidence. The score prioritizes research; it is not a buy recommendation.
Which Pharma - Animal company has the lowest comparable PEG?
Viyash Scientific Ltd has the lowest comparable PEG at 3.8, among 1 of 3 companies whose earnings and growth are steady enough for the ratio to mean anything.
How much history does this Pharma - Animal comparison include?
The page compares up to 20 reported quarters per company for fundamentals, returns and valuation, ending Jun 2026. Missing observations remain blank rather than being estimated.
How is the 4-Factor Sector Score calculated?
The four visible contributions add directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or stale evidence moves only the affected contribution toward neutral.
Is there a Nifty Pharma - Animal index?
NSE India maintains Nifty indices for several broad sector categories — Nifty Bank, Nifty IT, Nifty Pharma and others — but not for every sub-sector grouping on this site. Whether or not an official Nifty index covers Pharma - Animal, this page builds its own equal-weight basket of 3 listed Pharma - Animal companies — one company, one vote, regardless of market value — so no single large company dominates the reading. Figures are as of Jun 2026.
Which are the best Pharma - Animal stocks in India?
Ranked by this page's four-factor score, NGL Fine Chem Ltd places first among 3 listed Pharma - Animal companies, followed by Hester Biosciences Ltd. That is a ranking of published data — earnings, quality, valuation and market behaviour as of Jun 2026 — and not a recommendation; Sector Alpha is not registered with SEBI as an investment adviser.
How many Pharma - Animal stocks are listed in India?
This comparison covers 3 listed Pharma - Animal companies in India, each above the size floor the site applies, with 20 quarters of reported figures per company where the filings exist. The full ranked list is on this page, as of Jun 2026.
Which Pharma - Animal company is the biggest?
Viyash Scientific Ltd is the largest, with trailing-twelve-month revenue of ₹3,069 crore, ahead of NGL Fine Chem Ltd at ₹501 crore. That covers 3 of 3 companies with comparable reporting through Mar 2026.
Which Pharma - Animal company has the best profit margins?
Hester Biosciences Ltd has the highest operating margin at 29%, from 3 of 3 comparable companies. Viyash Scientific Ltd shows the biggest recent improvement, at +8 percentage points. A high margin matters most when it is holding or rising, not when it is peaking.
Which Pharma - Animal company makes the most profit?
Viyash Scientific Ltd earns the most, at ₹206 crore of trailing-twelve-month net profit, from 3 of 3 comparable companies. Hester Biosciences Ltd has the fastest profit growth at the ≥100% scoring cap, though growth off a small or recovering profit base overstates how much has actually changed.
Which Pharma - Animal company earns the highest return on capital?
NGL Fine Chem Ltd leads on return on capital employed at 18.6%, across 3 of 3 companies. Read it beside the length of its reported history: a high return that repeats for years is evidence of a durable business, while a single high reading can be a small capital base or one good year.
Which Pharma - Animal stock is the cheapest?
On PEG — where a LOWER number is cheaper — Viyash Scientific Ltd screens cheapest at 3.8×. Only 1 of 3 companies have earnings and growth steady enough for the ratio to mean anything, so this is not a sector-wide "cheapest stock" verdict. Cheap on a multiple is a reason to investigate, never a reason to buy on its own.
Is the Pharma - Animal sector beating the market?
Pharma - Animal has outperformed NIFTY 500 by 80.1% over the last 52 weeks and 34.1% over 13 weeks, measured on an equal-weight index of its current members. Inside the sector, 3 of 3 covered companies are beating the market on their own. Sector strength does not transfer evenly to every stock in it.
Which Pharma - Animal stock has the strongest price momentum?
NGL Fine Chem Ltd has the strongest relative strength against NIFTY 500. Relative strength answers last, after growth, quality and valuation: price can move well before the fundamentals confirm it, and sometimes without them confirming at all.
Which Pharma - Animal company scores highest for research priority?
NGL Fine Chem Ltd scores 71.6 out of 100 with 79.8% evidence confidence, from 32.1 points on growth and earnings, 17.2 on capital efficiency, 8.3 on valuation and 14 on relative strength. This ranks what deserves work next. It is not a buy recommendation, and management quality, catalysts and risk still need separate research.
How many Pharma - Animal companies does this comparison cover, and over what period?
It compares 3 listed companies over up to 20 reported quarters of fundamentals, ending Jun 2026, plus weekly price and relative-strength history. Membership is the full sector list — nothing is dropped for having thin data.
What is the total market cap of the Pharma - Animal sector?
The 3 Pharma - Animal companies on this page carry ₹16,261 crore of combined market value. Viyash Scientific Ltd is the largest at ₹12,101 crore, about 74% of the sector's total on its own. Market value moves with price, so this reading is dated 2026-08-13.
How is the Pharma - Animal sector performing?
3 of the 3 covered Pharma - Animal companies are beating NIFTY 500 on Mansfield relative strength. The sector itself is 80.1% ahead of NIFTY 500 over 52 weeks on an equal-weight index of its current members. Readings are as of 2026-08-13.
Why are some values on this page blank?
A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing observations are never interpolated, carried forward, or replaced with a similar-looking accounting line, and a company with missing evidence has its research score pulled toward neutral rather than being scored as bad.
Is this investment advice?
No. Every figure here is a deterministic calculation from reported company filings and market data, published for research. It contains no recommendation to buy or sell any security, does not account for your circumstances, and is not a substitute for advice from a licensed adviser.